Researchers at the UNC School of Medicine have developed a tool that can identify airway mucus abnormalities in patients with ...

Explore the core differences between Chemical Engineering and Process Engineering. Learn about their unique roles in R&D vs. production, their technical focus areas, and the diverse career paths ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

Dr. Berenika Maciejewicz, a triple-doctor and an expert in longevity, leads the company’s interdisciplinary team to ...

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

New insights by Aly Rahimtoola, founder of health-tech firm Bien-Etre suggest sleep disruption and cellular energy play a far ...

Groundhogs emerge from their burrows around Feb.4. This fits the folklore of Groundhog Day, but predicting the weather is not ...

SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company ...

Ahead of the launch of Artemis II, the first crewed mission to the moon in more than 50 years, astronauts share the movies ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...